Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia

Apoptosis. 2008 Jul;13(7):915-28. doi: 10.1007/s10495-008-0222-9.

Abstract

All-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) induce differentiation and apoptosis in acute promyelocytic leukemia (APL) cells. Here we investigated the role and regulation of death-associated protein-5 (DAP5/p97/NAT1), a novel inhibitor of translational initiation, in APL cell differentiation and apoptosis. We found that ATRA markedly induced DAP5/p97 protein and gene expression and nuclear translocation during terminal differentiation of APL (NB4) and HL60 cells but not differentiation-resistant cells (NB4.R1 and HL60R), which express very low levels of DAP5/p97. At the differentiation inducing concentrations, ATO (<0.5 microM), dimethyl sulfoxide, 1,25-dihydroxy-vitamin-D3, and phorbol-12-myristate 13-acetate also significantly induced DAP5/p97 expression in NB4 cells. However, ATO administered at apoptotic doses (1-2 microM) induced expression of DAP5/p86, a proapoptotic derivative of DAP5/p97. ATRA and ATO-induced expression of DAP5/p97 was associated with inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Furthermore, DAP5/p97 expression was upregulated by inhibition of the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway via LY294002 and via rapamycin. Finally, knockdown of DAP5/p97 expression by small interfering RNA inhibited ATRA-induced granulocytic differentiation and ATO-induced apoptosis. Together, our data reveal new roles for DAP5/p97 in ATRA-induced differentiation and ATO-induced apoptosis in APL and suggest a novel regulatory mechanism by which PI3K/Akt/mTOR pathway inhibition mediates ATRA- and ATO-induced expression of DAP5/p97.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Apoptosis / drug effects
  • Apoptosis / physiology
  • Apoptosis Regulatory Proteins / metabolism
  • Arsenic Trioxide
  • Arsenicals / pharmacology
  • Base Sequence
  • Cell Differentiation / drug effects
  • Cell Line, Tumor
  • Eukaryotic Initiation Factor-2 / metabolism
  • Eukaryotic Initiation Factor-4G / antagonists & inhibitors
  • Eukaryotic Initiation Factor-4G / genetics
  • Eukaryotic Initiation Factor-4G / metabolism*
  • Granulocytes / drug effects
  • Granulocytes / metabolism
  • Granulocytes / pathology
  • HL-60 Cells
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Leukemia, Promyelocytic, Acute / metabolism*
  • Leukemia, Promyelocytic, Acute / pathology*
  • Models, Biological
  • Oxides / pharmacology
  • Phosphatidylinositol 3-Kinases / metabolism
  • Protein Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • RNA, Small Interfering / genetics
  • RNA-Binding Proteins / metabolism
  • Signal Transduction
  • TOR Serine-Threonine Kinases
  • Tretinoin / pharmacology
  • Up-Regulation / drug effects

Substances

  • Apoptosis Regulatory Proteins
  • Arsenicals
  • EIF4G2 protein, human
  • Eukaryotic Initiation Factor-2
  • Eukaryotic Initiation Factor-4G
  • Oxides
  • PDCD4 protein, human
  • RNA, Small Interfering
  • RNA-Binding Proteins
  • Tretinoin
  • Protein Kinases
  • MTOR protein, human
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • Arsenic Trioxide